Clinical Trial

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test the safety of combining the disulfiram (DSF) and copper gluconate (Cu) to liposomal doxorubicin to treat patients with sarcomas that recurred or did not respond to initial treatment.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-01-14; most recent amendment 2026-06-04.
Status change: Not Yet Recruiting → Recruiting 2023-01-25
Trial Details
NCT Number NCT05210374
Lead Sponsor Case Comprehensive Cancer Center
Conditions Relapsed Sarcomas
Enrollment 24 participants
Start Date 2023-03-09
Primary Completion 2026-09-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-06